Attacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity

Area of Science:

• Immunology
• Oncology
• Cancer Vaccinology

Background:

• Cancer vaccines aim to enhance T cell-mediated anti-tumor immunity orchestrated by dendritic cells.
• Clinical implementation of cancer vaccination is limited by poor response, attributed to tumor-induced immunosuppression and poor antigen immunogenicity.
• Intratumor heterogeneity and neoantigen clonality are emerging factors influencing vaccine efficacy.

Purpose of the Study:

• To review recent studies on personalized tumor vaccines utilizing multiple neoantigens.
• To summarize advances in understanding intratumor mutational landscape, neoantigen presentation diversity, and their relation to immunogenicity.
• To highlight the need for characterizing neoantigens within the context of intratumor heterogeneity for improved vaccine efficacy.

Main Methods:

• Review of recent preclinical and clinical studies on personalized neoantigen-based tumor vaccines.
• Analysis of research on intratumor heterogeneity, mutational landscape, and neoantigen presentation.
• Synthesis of findings relating intratumor heterogeneity to tumor immunogenicity and vaccine response.

Main Results:

• Personalized tumor vaccines with multiple neoantigens can broaden and enhance anti-tumor immune responses.
• Intratumor heterogeneity involves diverse tumor cell subclones with temporal and spatial variations in neoantigen presentation and burden.
• These factors significantly impact tumor immunogenicity and response to vaccination.

Conclusions:

• Characterizing neoantigens within the context of intratumor heterogeneity is crucial for improving personalized cancer vaccine efficacy.
• Addressing tumor-induced immunosuppression and enhancing antigen immunogenicity remain critical challenges.
• Further research into the complex interplay of tumor heterogeneity and neoantigen presentation is warranted to advance cancer immunotherapy.